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REVIEW ARTICLE
Systematic reviews and meta-analysis of preclinical studies: why
perform them and how to appraise them critically
Emily S Sena1,2, Gillian L Currie1, Sarah K McCann2, Malcolm R Macleod1 and David W Howells2
The use of systematic review and meta-analysis of preclinical studies has become more common, including those of studies
describing the modeling of cerebrovascular diseases. Empirical evidence suggests that too many preclinical experiments lack
methodological rigor, and this leads to inﬂated treatment effects. The aim of this review is to describe the concepts of systematic
review and meta-analysis and consider how these tools may be used to provide empirical evidence to spur the ﬁeld to improve the
rigor of the conduct and reporting of preclinical research akin to their use in improving the conduct and reporting of randomized
controlled trials in clinical research. As with other research domains, systematic reviews are subject to bias. Therefore, we have also
suggested guidance for their conduct, reporting, and critical appraisal.
Journal of Cerebral Blood Flow & Metabolism advance online publication, 19 February 2014; doi:10.1038/jcbfm.2014.28
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INTRODUCTION
Animal models are invaluable tools for enriching our under-
standing of the mechanisms and etiology of human diseases. The
number of preclinical experiments performed each year continues
to increase and our understanding of disease mechanisms is
improving, but the number of novel interventions reaching the
clinic to treat cerebrovascular diseases continues to fall. It is clear
that there are limitations to the translational paradigm as it
currently exists. It is also clear from the sheer volume of preclinical
research that structured methods are required to make objective
sense of the available data. Systematic review and meta-analysis
are useful tools which can address some, but not all, of the
challenges of translational stroke research. They provide a less
biased summary of research ﬁndings and allow judgement of both
the range of available evidence (and hence the external validity)
and the likelihood that conclusions are at risk of bias (the internal
validity).
Systematic review sets out to use a structured process to
identify all data relevant to a speciﬁc research question. This may
be followed by meta-analysis, a statistical process that provides a
summary estimate of the outcomes from a group of studies, and
allows these outcomes from different groups of studies to be
compared. Although the ﬁrst meta-analysis was performed in
1904 by Karl Pearson, it was only in 1976 that Gene Glass coined
the term ‘meta-analysis’ to refer to this statistical pooling to allow
the integration of ﬁndings. He suggests that meta-analysis was
created out of the need to extract useful information from the
cryptic records of inferential data analyses in the abbreviated
reports of research in journals and other printed sources.1 Meta-
analysis is now used in many ﬁelds of research including
psychology, criminology, and education. Its use in clinical
medicine is routine, and the Cochrane Collaboration has been
instrumental in establishing the framework for evidence-based
healthcare to guide clinical practice and healthcare policy.
However, in preclinical research, the use of systematic review
and meta-analysis is relatively novel.
Glass considers necessity was the mother of invention where
meta-analysis is concerned; if it had not happened in the early
1970s, it was sure to happen soon after. We suggest that the same
holds for meta-analysis in preclinical stroke research. In the early
years of the millennium, the dogma had developed that ‘every-
thing works in animals, but nothing works in humans’. In 2006,
O’Collins et al2 published a review reporting that of more than 500
interventions that were reported to be efﬁcacious in animal
models of stroke, only thrombolysis with rtPA had been shown to
be effective in stroke patients. A search for in vivo animal stroke
studies published in the last 10 years yields more than 5,700
articles, but still no new therapies to treat acute stroke have been
developed. If the purpose of preclinical cerebrovascular research
was to develop new treatments for human stroke then clearly
there were substantial problems. The complexities of translational
research led our group, and others, to adapt the techniques of
meta-analysis, at that time largely restricted to clinical research,
to the preclinical domain, in an attempt to provide empirical
evidence for weaknesses in the prevailing translational paradigm,
evidence which might guide improvements in the translational
process.
In this narrative review, we aim to explain the concepts of
systematic review and meta-analysis; to describe how their use
changed clinical medicine; and to explore the contribution they
might make to preclinical research. We also describe some of the
elements to consider in the critical appraisal of systematic reviews
and meta-analyses of preclinical research.
THE CONCEPT
In any type of review, there are two fundamental steps that are
taken; identify the studies that are relevant to your research
questions and then synthesize these identiﬁed data to reach
conclusions. The beneﬁt of narrative reviews is that they include a
broad overview of relevant information, perhaps interpreted by an
experienced author tempered by years of practical knowledge of
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the ﬁeld; in many cases, they are highly useful. Unfortunately, they
also have limitations. The selection methods used to identify
studies that contribute to the review are often not transparent.
The credence given to individual studies is inherently subjective
and often unclear. Often, the reviewer themselves may be unable
to articulate the processes through which they reached the
conclusions presented. Systematic reviews are not bias free, but
the transparency of the methods used are designed to reduce
bias. In a systematic review, the researcher is required to outline
aims, objectives, and methodology. The principle is that an
independent researcher could perform the same identiﬁcation
process and yield the same data set. As is often the case, in the
interpretation of primary research studies, the conclusions drawn
from a meta-analysis may differ from one reviewer to the next.
However, the transparency and objectivity of the techniques used
provide a framework for these discussions.
The data synthesis process in meta-analysis has a number of
steps once the individual studies have been identiﬁed. First, the
effect sizes of individual studies are determined. This is often a
treatment effect that is a measure of the difference between
control and treatment groups. Effect sizes are not limited to
effects of drugs, but may represent a relationship between any
two variables. Second, the precision of an effect size is determined
by its standard error. The broad aim is to calculate an average
effect size across the studies, termed the summary estimate of
effect. Third, because some effect sizes are more precise than
others, this averaging process is often weighted so that more
precise studies are given more weight in a meta-analysis than less
precise ones. Finally, the differences between the component
effect sizes—the heterogeneity–are assessed. We expect variation
of effect sizes to occur due both to random error and to real differ-
ences in experimental design. In our view, it is this exploration of
sources of heterogeneity—the identiﬁcation of those aspects of
experimental design that cause exaggerations or underestima-
tions in treatment effects, or those aspects of drug delivery that
give maximum efﬁcacy—which is the true strength of meta-
analysis. However, because we are simply observing a ‘‘cohort’’ of
experiments, rather than testing the impact of these inﬂuences
experimentally, ﬁndings from meta-analysis should be considered
hypothesis generating rather than conﬁrmatory.
IN CLINICAL RESEARCH
Although systematic reviews and meta-analyses are now routinely
used by medical researchers to inform practice and policy, they
also had a pivotal role in providing empirical evidence of the
impact of bias in the conduct of controlled clinical trials. Chalmers
and others provided evidence that studies that do not adequately
mask treatment allocation are associated with bias and inﬂated
treatment effects.3,4 In the hierarchy of evidence randomized
controlled trials are now considered the gold standard in clinical
trial design. Conceptually, the ability of randomization to account
for systematic differences in factors, known or unknown, between
groups that may affect outcome is apparent; as is ensuring that
preconceived views of patients and clinicians do not bias the
assessment of outcomes.5 But it required empirical evidence to
revolutionize clinical research and to convince trialists of the
importance of methodological rigor in both the conduct and
reporting of their studies.6
WHAT COULD META-ANALYSIS DO FOR PRECLINICAL
RESEARCH?
Across the modeling of a number of cerebrovascular diseases,
there is a considerable volume of often conﬂicting data.
Systematic review and meta-analysis can be used to describe
which interventions have been tested in models of disease, to
provide an indication of the attrition rate of interventions (i.e., the
number of interventions not progressing to clinical trial), and to
describe the range of conditions under which efﬁcacy has been
tested. Furthermore, pooling data using meta-analysis can be used
to assess both the overall efﬁcacy of an intervention and the
impact of factors relating to internal and external validity, giving
valuable insights into the causes of translational successes and
failures.
In recent years we, and others, have presented empirical
evidence that suggests that the usefulness of data from
experiments testing drug efﬁcacy in animal models of various
neurologic diseases may be substantially impaired by limited
methodological quality, limited generalizability, and by signiﬁcant
publication bias.7–10
Methodological Quality
In an experiment, the credibility of the inferred causal relationship
between treatment and outcome is dependent upon on the
statistical power and internal validity.
Preclinical animal research is confounded by pressures to
reduce the number of animals used because of concerns about
cost, time, ethics, and practicalities of disease modeling that might
lead to studies either being underpowered or of unknown power.
Determining the required sample size to answer a research
question is crucial. Too small and the results are imprecise and
lack statistical power. Too large and unnecessary costs are
incurred. A priori sample size calculations also provide assurance
that animals are not added to a study incrementally in response to
(unreported) interim analyses.
The internal validity of an experiment ensures that the changes
observed in outcomes are due to an induced change in one or
more of the independent variables rather than some other
confounding factor. The internal validity of an experiment may be
threatened by a range of biases. These include, but are not limited
to, selection bias, performance bias, and detection bias. Selection
bias occurs when there are systematic differences between study
groups at the start of an experiment. Performance bias occurs
when systematic differences occur in how the groups are handled
during a study and detection bias occurs when systematic
differences occur between groups in how outcomes are
ascertained, diagnosed, or veriﬁed. Measures to reduce the impact
of these biases include randomization, allocation concealment
and masked assessment of outcome.
Systematic review and meta-analysis of experimental studies
covering a range of neurologic disorders have provided evidence
that few studies take measures to reduce bias or perform formal
power calculations to determine sample size (Table 1).
Meta-analysis can be used to assess the impact of methodo-
logical quality on reported outcomes. Unfortunately, sample size
calculations are so seldom reported that it has not been possible
to assess whether performing a sample size calculation inﬂuences
outcome. However, in animal models of experimental autoim-
mune encephalomyelitis, we showed that reported efﬁcacy was
largest in the smallest studies11 (Figure 1).
Fortunately, we have been able to generate empirical evidence
describing the impact of reporting of measures to reduce bias on
outcome. In a meta-analysis of therapeutic hypothermia in
experimental stroke, we observed treatment effects were 10%
larger in non-randomized studies and 8% larger in unmasked
studies than those that did take these measures to reduce bias.12
Similarly, in a meta-analysis of NXY-059 in experimental stroke,
NXY-059 was reported to be 30% more effective in studies that
were not randomized or masked than in studies that reported
randomization and blinding.13
External and Construct Validity
If preclinical models of disease are to inform human health,
experiments require external validity and the models used require
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construct validity; both types of validity relate to the general-
izability of a study. External validity refers to the ability to
generalize the ﬁndings to different measures, settings, and times.
Construct validity refers to adequate representation of theoretical
constructs, in disease modeling this may be threatened where
only speciﬁc characteristics of a complex disease are modeled.
Aspects of both these validity types are clearly disease speciﬁc.
For example, in the modeling of ischemic stroke, associated
co-morbidities, age of animals, and the time to treatment are
important factors. Using systematic review, we have identiﬁed that
the majority of preclinical stroke studies use young male
normotensive rats. Furthermore, meta-analysis has also provided
evidence of no detectable effect of either tissue plasminogen
activator or NXY-059 in hypertensive animals,13,14 which would
appear to be concordant with results in humans.
The most common recommendations from preclinical research
guidelines to improve external validity are that experiments
should be replicated in different models of the same disease,
in different species and that ﬁndings should be replicated
independently.15 Others recommend that the time that
treatment is started after disease/injury induction should be
realistic in terms of what is possible in the clinic.16 The most
common recommendations to improve construct validity include
characterization of disease phenotype in the animal model before
experimentation, matching the model to the human disease and
matching outcome measures to the clinical setting.15
Reporting Bias
The validity of a systematic review may be limited by reporting
biases of the component studies. It has long been recognized that
neutral studies often remain unpublished or take longer to get
published than those reporting statistically signiﬁcant results. They
are also more likely to be published in journals of low impact or in
languages other than English.17 Such work is less likely to be
identiﬁed in narrative and even in systematic review, and such
publication bias can lead to the overstatement of summary effects
in meta-analysis. Published meta-analyses now routinely report
the presence or lack of publication bias in their reviews.
Data from meta-analyses of 525 unique publications and 16
interventions tested in models of experimental stroke were
combined and imprecise study effects consistent with publication
bias were seen in funnel plot asymmetry and conﬁrmed with
Egger Regression (Figures 2A and 2B). Using a meta-analytical
technique known as trim-and-ﬁll that imputes theoretical missing
studies, the overall efﬁcacy was signiﬁcantly reduced from 30.1%
(28.7 to 31.6%) to 23.3% (21.7 to 24.9%), a relative overstatement
in efﬁcacy of 31%. Two hundred studies were deemed to be
missing and were ‘ﬁlled’ into the data set (Figure 2C). Furthermore,
only 2% of publications reported no signiﬁcant treatment effects.9
Other reporting biases that are less commonly assessed in
systematic reviews include selective outcome reporting and
selective analysis reporting. These biases may occur where many
outcome measures are assessed or many statistical analyses are
performed but only the ‘best’ results are presented. This in turn
leads to a body of evidence with an inﬂated proportion of
statistically signiﬁcant results.18 In a review of 160 meta-analyses
including 4,445 experiments from the modeling of six neuro-
logic disorders (Alzheimer’s, encephalomyelitis, focal ischemia,
intracerebral hemorrhage, Parkinson’s disease, and spinal cord
injury) we assessed, using the Excess Signiﬁcance Test, whether
too many of the individual studies in the meta-analyses reported
statistically signiﬁcant results.10 We expected 21% of the results to
be signiﬁcant but observed 39% signiﬁcant results, suggesting the
presence of bias in this data set. These issues may, in part, be
addressed by the use of published protocols.
Table 1. Number and percentages of studies across the modeling of different neurologic diseases reporting measures to reduce the risk of bias
Number of
publications
Masked assessment of
outcome (%)
Random allocation to
group (%)
Allocation
concealment (%)
Sample size
calculation (%)
Alzheimer’s
disease30
428 95 (22) 67 (16) NA 0 (0)
Multiple sclerosis11 1,117 178 (16) 106 (9) NA 2 (o1)
Parkinson’s disease31 252 38 (15) 40 (16) NA 1 (o1)
Intracerebral
hemorrhage32
88 43 (49) 27 (31) 7 (8) 0 (0)
Focal ischemia
NXY 05913 9 4 (44) 3 (33) 5 (56) 2 (22)
Hypothermia12 101 38 (38) 36 (36) 4 (4) 0 (0)
Erythropoietin33 19 8 (42) 7 (37) 4 (21) 0 (0)
Tirilazad34 18 13 (72) 12 (67) 1 (6) 0 (0)
tPA14 113 24 (21) 42 (37) 23 (20) 8 (7)
NA, not applicable; tPA, tissue plasminogen activator.
Figure 1. The effect of the mean sample size on the estimate of
effect size for neurobehavioural score in models of encephalomye-
litis. The horizontal gray bar represents the 95% confidence limits for
the summary estimate of effect. The vertical error bars represent the
95% confidence intervals for the individual estimate. The widths of
the bar represent the log of the number of animals contributing to
that comparison.11
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HOW TO APPRAISE CRITICALLY A SYSTEMATIC REVIEW AND
META-ANALYSIS OF PRECLINICAL STUDIES
In a systematic review of systematic reviews of preclinical studies,
Mignini and Khan found that 30% speciﬁed a testable hypothesis,
27% performed a literature search without language restrictions,
17% assessed for the presence of publication bias, half assessed
study validity, and 2% investigated sources of heterogeneity.19 As
with any type of research, systematic reviews and meta-analyses
are susceptible to bias, and it is only through clear reporting of
what was done that it is possible to assess this risk of bias.
As systematic reviews and meta-analyses of preclinical research
become more common, a number of different approaches have
been used and readers—and reviewers—need to be able to
assess whether the methodologies used are sound and the
interpretation is valid. However, we are not aware of any study
that provides empirical evidence of the presence or magnitude of
the risk of bias associated with different aspects of the conduct or
reporting of systematic reviews and meta-analyses of data from
in vivo experiments.
Without such data, guidelines have less validity, but in a
developing ﬁeld, it is, we believe, reasonable to make some
recommendations, based in part on our experience in conducting
such reviews and in part on guidelines in other, related ﬁelds. In
Table 2, we make some recommendations for reporting systema-
tic reviews and meta-analyses of animal studies using key
elements of the guidelines proposed by Peters et al20 that are
akin to the PRISMA guidelines for the reporting of systematic
reviews and meta-analyses of healthcare interventions in human
clinical studies.21 We suggest the following steps should be
considered in the critical appraisal of a systematic review and
meta-analysis (Table 3; adapted from Garg et al22).
Does the Study Follow a Pre-Speciﬁed Protocol?
If a protocol exists, the manuscript should provide a reference to
where it might be found.
A pre-speciﬁed written protocol is likely to improve the
standard of a systematic review and meta-analysis by reducing
the risk of ‘data dredging’ and post hoc revisions of study aims.
Making the protocol publicly available to the research community
also allows reviewers to obtain feedback on drafts through peer
review. It is often the case that protocols evolve during the course
of the review in light of clearer understanding of the research ﬁeld
and the data available; if such iterations occur, the changes should
be justiﬁed and the date of these changes should be given in a
revised protocol. The protocol should clearly deﬁne the research
question, objectives, inclusion criteria, search strategy, data
collection processes, and data analysis plan. A protocol should
allow readers to judge whether the ﬁnal study did indeed follow a
pre-speciﬁed plan.
Was the Research Question Focused and Clearly Deﬁned?
The manuscript should provide a clear statement of the research
question that is addressed
As with any study, the research question of a systematic review
and meta-analysis needs to be focussed and clearly deﬁned. It also
needs to be appropriate to the type of study being performed,
and its answer meaningful to the ﬁeld.
Are the Inclusion Criteria Appropriate?
The manuscript should deﬁne clear inclusion and exclusion criteria
relating to the identiﬁcation of relevant publications.
The reader should be conﬁdent that the eligibility criteria for
inclusion in a systematic review are not biased and are appro-
priate to the research questions being asked. The scope of the
inclusion criteria determines the validity of the conclusions drawn.
There has been a debate on how broad or narrow the selection
process should be;23 some argue that only studies that meet a
high standard of methodological quality should be included24
while others argue that meta-analyses should deal with the good,
bad, and indifferent of included studies.1 There is no correct
approach but the degree of caution with which the results are
interpreted and conclusions drawn should take this into account.
Some reviews are restricted to studies published in English, we
suspect because of the ease of data abstraction. Language bias
occurs if studies performed in non-English speaking countries are
more likely to publish their statistically signiﬁcant results in English
Figure 2. Publication bias. Plots describing (A) funnel plot, (B) Egger
regression, and (C) trim-and-fill.9
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language journals and non-signiﬁcant results in non-English
language journals.25 The impact of language bias on systematic
reviews of preclinical data is yet to be determined. It may not be
always practical to translate all non-English studies, but the
reviewers should at least identify and report how many studies
were excluded for reason of language. This is usually possible as
titles and abstracts are often translated even if the full papers are
not.
How Comprehensive was the Search Strategy?
The manuscript should deﬁne the search strategy, including the
search terms used, the databases searched, and the date(s) of the
search(es).
The number of investigators screening publications for inclu-
sion, and the method for dealing with inconsistencies, should be
described.
Identifying relevant studies for a systematic review can be
arduous. Biomedical journals are the most common source of
relevant data and these are identiﬁed via the searching of
bibliographic databases. A range of bibliographic databases
should be searched as no database has complete coverage of
all health-related literature. The core databases used are Medline
and Embase; Medline is often searched via PubMed, but other
search services may be used. Embase indexes more European and
Asian journals and has roughly a 60% overlap with Medline. There
are other sources of data that may be appropriate, including other
specialized databases, conference proceedings, personal commu-
nications, and books.
The search strategy used needs to be comprehensive enough to
identify most relevant studies. The screening of identiﬁed studies
for inclusion is susceptible to random error and may be subjective.
For this reason, we advise that two independent reviewers screen
studies for inclusion, and the number of reviewers should be
reported in the manuscript.
A comprehensive search reduces the possibility of publication
bias in a review. Publication bias may be present because of an
incomplete search of the literature or because the studies
themselves are not in the public domain to be identiﬁed in the
search process. There are various techniques for assessing for the
presence and impact of publication bias in a meta-analysis17 that
reviewers should consider.
Was the Data Abstraction from Each Study Appropriate?
The choice of data (times, outcome measures) to be extracted
from each publication should be deﬁned.
The number of investigators extracting data from publications,
and the method for dealing with inconsistencies, should be
described.
The reviewers should be rigorous and their methods reprodu-
cible in extracting data for included studies. Ideally, this process
should also be performed by two independent reviewers.
The assessment of methodological quality of included studies
should be reported. Understanding the rigor and validity of
included studies is important in the interpretation of the con-
clusions drawn.
Were the Data Pooled Appropriately?
The manuscript should identify a primary outcome variable or the
statistical limits to any subdivision of the data.
The manuscript should describe the method of pooling of
data and provide summary estimates, estimates of uncertainty
(e.g. 95% conﬁdence intervals), and a measure of heterogeneity
(e.g. Q, I2).
The statistical pooling of aggregate data in a meta-analysis
gives greater weight to more precise studies. The assumption of
this pooling may be performed under a ‘ﬁxed’ or ‘random’ effects
Table 2. Guidelines for reporting systematic reviews and meta-analyses of animal studies
Title Identify the report as a systematic review and/or meta-analysis of animal experiments.
Abstract Provide a structured abstract covering the following: objectives, data sources, review methods, results, and
conclusion.
Introduction Clearly defined and focussed research question.
Methods
Protocol Indicate if a protocol exists and where it can be found (i.e., web address).
Searching Describe the information sources in detail, including keywords, search strategy, any restrictions, and special efforts to
include all available data.
Selection Describe the inclusion and exclusion criteria.
Validity and quality
assessment
Describe the criteria and process used to assess validity.
Data abstraction Describe the process or processes used (e.g., completed independently, in duplicate).
Describe whether aggregate data or individual animal data are abstracted.
Study characteristics Describe the study characteristics relevant to your research question.
Quantitative data
synthesis
Describe the principal measures of effect, method of combining results, handling of missing data; how statistical
heterogeneity was assessed; and any assessment of publication bias—all in enough detail to allow replication.
Results
Flow chart A meta-analysis profile summarizing study flow giving total number of experiments in the meta-analysis.
Study characteristics Descriptive data for each experiment.
Quantitative data
synthesis
Present simple summary results (e.g., forest plot); identify sources of heterogeneity, impact of study quality, and
publication bias.
Discussion Summarize the main findings; discuss limitations;
provide general interpretation of the results in the context of other findings, and implications for future research.
Funding Describe sources of funding for the review and other support. The role of funders should be presented.
Conflict of interest Any potential conflict of interests should be reported.
Table 3. Points to consider in the critical appraisal of systematic
reviews and meta-analyses of animal studies
1. Does the study follow a pre-specified protocol?
2. Was the research question focused and clearly defined?
3. Are the inclusion criteria appropriate?
4. How comprehensive was the search strategy?
5. Was the data abstraction from each study appropriate?
6. Were the data pooled appropriately?
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model. More detailed discussion of the merits of each model in
the pooling of preclinical data can be found elsewhere26 but on
the whole, given the heterogeneity often observed in preclinical
studies, random effects meta-analysis is more appropriate. Formal
assessment of heterogeneity should be performed. Attempts to
stratify data to account for, or explain, some of the heterogeneity
are useful.
SUMMARY
Recent years have seen improvements in the conduct and
reporting of clinical trial design after the publication of the
CONSORT statement.27 Analogous to this, the ARRIVE guidelines28
and Landis paper29 hope to promote the same improvements in
animal experiments.
Systematic review and meta-analysis have provided empirical
evidence that too many preclinical experiments lack methodolo-
gical rigor, and this leads to inﬂated treatment effects. There is
of course no guarantee that improvements in the validity of
preclinical animal studies and reduced publication bias will
improve the translational hit of interventions from bench to
bedside. However, we hope that the mounting empirical evidence
drives the preclinical research community toward improved rigor.
Despite some very reasonable concerns about the novelty of the
methodological approach and the difﬁculty of conﬁrming these
hypotheses experimentally, ﬁndings from meta-analyses cover
such a wide range of disease models and have been reported by
so many different research groups that it is highly unlikely that
these conclusions do not reﬂect a real and present problem with
the use of animal models. As consumers of systematic reviews and
meta-analyses of preclinical research, it is important that we are
able to discern, as we do for primary research studies, the rigor
with which the meta-analyses are performed and reported.
We hope that this empirical evidence of bias, akin to that
reported in clinical research more than 30 years ago, spurs a
similar change in the way we conduct and report preclinical
research. Whether this leads to improved translation we are yet to
see. However, what we will observe is an improvement in the
conduct and reporting of preclinical research that reasonably can
only be of beneﬁt to this troubled ﬁeld of research.
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